Patents by Inventor Anke Kretz-Rommel

Anke Kretz-Rommel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20230348589
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: January 27, 2023
    Publication date: November 2, 2023
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR
    Publication number: 20230159634
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: July 29, 2022
    Publication date: May 25, 2023
    Inventors: Anke Kretz-Rommel, Roger Ferrini
  • Treatment of disease responsive to modulation of cannabanoid 1(CB1) receptor signaling
    Patent number: 11566069
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Bird Rock Bio, Inc.
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Antibodies that bind human cannabinoid 1 (CB1) receptor
    Patent number: 11421026
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 23, 2022
    Assignee: Bird Rock Bio, Inc.
    Inventors: Anke Kretz-Rommel, Roger Ferrini
  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20190315856
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 17, 2019
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Antibodies that bind human cannabinoid 1 (CB1) receptor
    Patent number: 10308712
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 4, 2019
    Assignee: BIRD ROCK BIO, INC.
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR
    Publication number: 20180282406
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: September 27, 2016
    Publication date: October 4, 2018
    Inventors: Anke Kretz-Rommel, Roger Ferrini
  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20170210797
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 27, 2017
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
    Patent number: 9249229
    Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: February 2, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel
  • POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF
    Publication number: 20150368341
    Abstract: Small animal models for assessing immunomodulatory effects of compounds are provided.
    Type: Application
    Filed: February 24, 2015
    Publication date: December 24, 2015
    Inventors: Katherine S. BOWDISH, Anke KRETZ-ROMMEL
  • Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
    Patent number: 9150661
    Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: October 6, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
  • Antibodies to OX-2/CD200 and uses thereof
    Patent number: 9000133
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: April 7, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Polypeptides and antibodies derived from chronic lymphocytic Leukemia cells and uses thereof
    Patent number: 8999328
    Abstract: Small animal models for assessing immunomodulatory effects of compounds are provided.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: April 7, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel
  • Antibodies to OX-2/CD200 and uses thereof
    Patent number: 8709415
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: April 29, 2014
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF
    Publication number: 20130158236
    Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
    Type: Application
    Filed: January 5, 2012
    Publication date: June 20, 2013
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
  • ANTIBODIES TO OX-2/CD200 AND USES THEREOF
    Publication number: 20120148579
    Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.
    Type: Application
    Filed: December 6, 2011
    Publication date: June 14, 2012
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Susan Faas McKnight, Jeremy P. Springhorn, Dayang Wu
  • Polypeptides that Bind TRAIL-R1 and TRAIL-R2
    Publication number: 20120135938
    Abstract: Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 31, 2012
    Applicant: ANAPHORE, INC.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Mark Renshaw, Bing Lin, Martha Wild
  • METHOD OF TREATING AUTOIMMUNE DISEASE BY INDUCING ANTIGEN PRESENTATION BY TOLERANCE INDUCING ANTIGEN PRESENTING CELLS
    Publication number: 20120107301
    Abstract: Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.
    Type: Application
    Filed: August 24, 2011
    Publication date: May 3, 2012
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, Anke Kretz-Rommel, Naveen Dakappagari
  • Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
    Patent number: 8114403
    Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: February 14, 2012
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
  • Polypeptides that Bind TRAIL-R1 and TRAIL-R2
    Publication number: 20120021995
    Abstract: Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.
    Type: Application
    Filed: July 26, 2011
    Publication date: January 26, 2012
    Applicant: ANAPHORE, INC.
    Inventors: Katherine Bowdish, Anke Kretz-Rommel, Mark Renshaw, Bing Lin, Jean de Silva Correia, Roger Ferrini, Elise Chen